Equities research analysts at Guggenheim initiated coverage on shares of Endo International (NASDAQ:ENDP) (TSE:ENL) in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The brokerage set a “neutral” rating and a $8.50 price target on the stock. Guggenheim’s price objective points to a potential upside of 6.25% from the stock’s previous close.

A number of other brokerages have also commented on ENDP. Goldman Sachs Group initiated coverage on Endo International in a research note on Thursday, September 28th. They issued a “sell” rating and a $7.00 price target for the company. Royal Bank of Canada dropped their price target on Endo International from $9.00 to $8.00 and set a “sector perform” rating for the company in a research note on Friday, November 10th. Cantor Fitzgerald dropped their price target on Endo International from $9.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, November 10th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $9.00 price target on shares of Endo International in a research note on Sunday, September 17th. Finally, Mizuho reaffirmed a “buy” rating and issued a $14.00 price target (down previously from $19.00) on shares of Endo International in a research note on Tuesday, September 12th. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $11.48.

Endo International (ENDP) traded up $0.19 during trading hours on Tuesday, hitting $8.00. The stock had a trading volume of 4,834,795 shares, compared to its average volume of 5,590,000. The stock has a market capitalization of $1,790.00, a price-to-earnings ratio of 1.65, a PEG ratio of 2.18 and a beta of 0.59. Endo International has a 52-week low of $5.77 and a 52-week high of $17.99. The company has a debt-to-equity ratio of 10.78, a quick ratio of 0.86 and a current ratio of 1.08.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. The firm had revenue of $786.90 million during the quarter, compared to analyst estimates of $794.93 million. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The business’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.01 earnings per share. equities research analysts forecast that Endo International will post 3.67 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the company. Cornerstone Capital Management Holdings LLC. increased its holdings in shares of Endo International by 64.0% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 135,627 shares of the company’s stock valued at $1,160,000 after acquiring an additional 52,927 shares in the last quarter. LMR Partners LLP bought a new position in shares of Endo International during the third quarter valued at $148,000. Van ECK Associates Corp increased its holdings in shares of Endo International by 67.1% during the third quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock valued at $2,921,000 after acquiring an additional 136,873 shares in the last quarter. Alps Advisors Inc. increased its holdings in shares of Endo International by 9.3% during the third quarter. Alps Advisors Inc. now owns 250,511 shares of the company’s stock valued at $2,146,000 after acquiring an additional 21,373 shares in the last quarter. Finally, Gamco Investors INC. ET AL increased its holdings in shares of Endo International by 76.2% during the third quarter. Gamco Investors INC. ET AL now owns 110,500 shares of the company’s stock valued at $946,000 after acquiring an additional 47,800 shares in the last quarter. Hedge funds and other institutional investors own 93.17% of the company’s stock.

WARNING: “Endo International (ENDP) Research Coverage Started at Guggenheim” was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/12/17/endo-international-endp-research-coverage-started-at-guggenheim.html.

About Endo International

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.